Exercise of options and total voting rights

2 June 2026

Fusion Antibodies plc

("Fusion" or the "Company")

Exercise of options and total voting rights

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the exercise of options by an employee of the Company.

The employee has exercised options over 135,000 ordinary shares of 4p each in the Company ("Ordinary Shares") at an exercise price of 4.25p per option. To satisfy the exercise the Company is issuing 135,000 new Ordinary Shares (the "New Ordinary Shares"). Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will be effective, and dealings will commence in respect of the New Ordinary Shares at 8.00 a.m. on or around 8 June 2026.

Following Admission, the Company will have 125,156,878 Ordinary Shares in issue. The Company does not currently hold any shares in treasury and therefore this figure may be used by shareholders in the Company as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries: 

Investor Hub

We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/rJaa9e

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.